



JONES PHARMA INCORPORATED
1945 Craig Road, P.O. Box 46903
St. Louis, Missouri 63146
314 576-6100 Fax 314 469-5749
www.jmedpharma.com

May 14, 2001

SENT VIA FACSIMILE AND FEDERAL EXPRESS

John Jenkins, M.D. Acting Director
Division of Metabolism and Endocrine Drug Products (HFD-510)
Document Control Room 14B-19
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

**RE: Debarment Certification
NDA 21-301
Levoxyl (levothyroxine sodium tablets, USP)**

Reference is made to our New Drug Application for Levoxyl (Levothyroxine Sodium Tablets, USP) NDA 21-301 submitted July 28, 2000.

By this letter, it is certified that JONES PHARMA INCORPORATED (JPI) did not and will not use in any capacity the services of any person debarred under Section 306(k)(1) in connection with this NDA application for LEVOXYL (Levothyroxine Sodium Tablets, USP).

JPI also certifies that the company has not used any person or affiliate person/firm for whom convictions subject to debarment have occurred in the last five years in any capacity in connection with the development of this product.

If there are any questions concerning this submission, please do not hesitate to contact me by telephone at (314) 576-6100 or by fax at (314) 205-9497.

Sincerely,

JONES PHARMA INCORPORATED
(A subsidiary of King Pharmaceuticals, Inc.)

Nancy Cafmeyer
Director, Regulatory Affairs